




Financial tear sheet

Corporate Profile

2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.

Stock Information

BAX (BAX)	
Exchange	NYSE (US Dollar)
Price	\$64.29
Change (%)	▼ 1.26 (1.92%)
Volume	2,410,915
52 Week Low	\$51.39
Market Cap	\$35,406,099,323
Rolling EPS	2.38
PE Ratio	27.5259
Shares Outstanding	540,138,815
Data as of 03/23/2018 4:00 PM ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

DATE	TITLE
03/19/18	Baxter Completes Acquisition of RECOTHROM and PREVELEAK to Broaden Surgical Hemostat and Sealant Portfolio
02/20/18	Baxter Declares Quarterly Dividend and Announces Expanded Share Repurchase Authorization
02/13/18	Baxter to Present at the Barclays Global Healthcare Conference

Recent & Upcoming Events

DATE	TITLE
02/01/2018 7:30 AM CT	Q4 2017 Baxter International Inc. Earnings Conference Call
02/13/2018 10:15 AM ET	Barclays Global Healthcare Conference Location Miami, FL
02/14/2018 11:30 AM ET	7th Annual Leerink Partners Global Healthcare Conference Location New York

SEC Filings

FILING DATE	FORM
03/07/18	4
03/07/18	4
03/07/18	4
03/07/18	4

Primary IR Contact

Clare Trachtman
Baxter International Inc.
Phone: 224-948-3085